Navigation Links
Archemix Announces Completion of Phase 1 Trial of ARC1779

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 8, 2007 - Archemix Corp., a biotechnology company focused on discovering and developing aptamers, announced the successful completion of a Phase 1 study of its novel aptamer therapeutic, ARC1779. ARC1779 is designed to selectively block the activation, adhesion and aggregation of platelets by inhibiting the binding of von Willebrand Factor (vWF) to the GPIb receptor on platelets. Activated vWF is scientifically recognized as the first stage of arterial thrombus formation and plays a significant role in the development of harmful blood clots. Archemix plans to develop ARC1779 as an anti-thrombotic drug for use in angioplasty and in a rare blood disorder that is mediated by vWF known as thrombotic thrombocytopenic purpura, or TTP.

Archemix plans to present a complete data set from this Phase 1 clinical trial within a peer-reviewed forum in 2007.

Based on the proof-of-mechanism data from this Phase 1 study, Archemix plans to commence a Phase 2 study of ARC1779 to evaluate the safety and efficacy of ARC1779 in acute coronary syndrome patients during the fourth quarter of 2007. Additionally, Archemix plans to initiate a Phase 1b study of ARC1779 in patients suffering from TTP in the fourth quarter of 2007. Approximately 3,000 new cases of TTP are diagnosed per year in the United States, but currently there is no approved drug therapy for the disease.

"We are very pleased to demonstrate ARC1779 can inhibit vWF activation and platelet function, which are both widely recognized as playing critical roles in clot formation which can critically impede blood flow to the heart," said Jim Gilbert, M.D., Chief Medical Officer, Archemix. "In Phase 2, we hope to show that using ARC1779 during angioplasty may improve myocardial perfusion by reducing blood clots in the coronary microcirculation while also providing effective anti-thrombotic treatment at the primary site of arte rial blockage."

"We are developing a pipeline of aptamer therapeutics with a proprietary focus in acute cardiovascular and hematological diseases," commented Errol De Souza, Ph.D., President and Chief Executive Officer, Archemix. "The advancement of ARC1779 into Phase 2 will be a key milestone in the development of our broad product portfolio."

About Aptamers

Aptamers are single-stranded nucleic acids that form well-defined three dimensional shapes, allowing them to bind target molecules in a manner that is conceptually similar to antibodies. Aptamers combine the optimal characteristics of small molecules and antibodies, including high specificity and affinity, chemical stability, low immunogenicity and the ability to target protein-protein interactions. In contrast to monoclonal antibodies, aptamers are chemically synthesized rather than biologically expressed.

About Archemix

Archemix Corp. is a privately-held biopharmaceutical company developing aptamers as a class of directed therapeutics for the prevention and treatment of human disease. The company is leveraging its proprietary drug discovery technology to fuel the growth of its development portfolio, which is primarily focused on acute cardiovascular and hematology diseases and cancer. Archemix's broad product pipeline, being developed both by the company as well as its licensees, includes multiple investigational compounds at various stages of development, several of which are moving into Phase 2 clinical trials. Archemix's lead proprietary product, ARC1779, a selective platelet inhibitor, is anticipated to start a Phase 2a and Phase 1b clinical trial before the end of 2007. Archemix' leadership position in intellectual property, technology and expertise relating to aptamers has enabled it to form numerous collaborations with biotechnology and pharmaceutical collaborators, including Merck Serono, Pfizer Inc., Elan Pharma, Nuvelo, Inc., Antisoma plc., and Regado Biosciences. For more information, please visit www.archemix.com.

Contact

Media
Yates and Associates
Kathryn Morris, Tel: 845-635-9828
or
Investor
Stern Investor Relations, Inc.
Lilian Stern, Tel: 212-362-1200
lilian@sternir.com


'"/>




Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Juan Monteverde , founder and managing ... boutique securities firm headquartered at the Empire State Building ... that a class action lawsuit has been filed in the ... Inotek Pharmaceuticals Corporation (NASDAQ:  ITEK)("Inotek" or the "Company") on ... 2015 and December 30, 2016, inclusive (the "Class Period").  ...
(Date:2/24/2017)... Report analyzes the worldwide markets for Endodontic Supplies in US$ ... Canada , Japan , ... Latin America , and Rest of World. ... through 2022. Also, a six-year historic analysis is provided for ... and secondary research. Company profiles are primarily based on public ...
(Date:2/24/2017)... le 24 février 2017 ITL Limited, ( ASX : ITD ... est ravie d,annoncer les excellents résultats semestriels clos le ... correspondante. Une présentation complète « Résultats et mise à jour ... ici . Faits marquants ... 2015 : 1,04 million $ ; en hausse de 104 %) ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... ... The narrative in “ Signal 8: An Australian Paramedic’s Story ” (published ... experiences. Schanssema describes the tragedies he saw, as well as his struggles with grief ... initially unsure of the career path he wanted to take, found fulfillment in a ...
(Date:2/24/2017)... ... ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer recently announced that ... Chairman of the Management Committee when IFN was originally formed in 2002 where he ... and development of the business plan. He became the first paid employee of ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most award-winning sunscreen ... Fondo of Marin. For the second year in a row, cyclists will stay ... “We are thrilled to provide our safe, non-toxic sunscreen to over 2,000 cycling ...
(Date:2/23/2017)... ... February 23, 2017 , ... The American Cleft Palate-Craniofacial Association (ACPA) is pleased ... KLS is a longtime supporter of the event. , "We are pleased that KLS ... Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has a long track record of ...
(Date:2/23/2017)... Los Angeles, California (PRWEB) , ... February 23, ... ... for Global Sports Development will host a diverse symposium on “Doping ... School of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will ...
Breaking Medicine News(10 mins):